Maze Therapeutics, Inc.
MAZE
$25.56
-$0.87-3.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.00M | -- | 0.00 | 2.50M | 167.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.00M | -- | 0.00 | 2.50M | 167.50M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 20.00M | -- | 0.00 | 2.50M | 167.50M |
| SG&A Expenses | 39.04M | 34.45M | 31.47M | 30.57M | 28.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 154.05M | 142.90M | 134.57M | 128.33M | 117.30M |
| Operating Income | -134.05M | -142.90M | -134.57M | -125.83M | 50.20M |
| Income Before Tax | -122.54M | -131.12M | -126.41M | -121.35M | 53.11M |
| Income Tax Expenses | -- | -- | -275.00K | -554.00K | 1.17M |
| Earnings from Continuing Operations | -122.54 | -131.12 | -126.13 | -120.80 | 51.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.54M | -131.12M | -126.13M | -120.80M | 51.94M |
| EBIT | -134.05M | -142.90M | -134.57M | -125.83M | 50.20M |
| EBITDA | -131.89M | -140.50M | -131.96M | -123.00M | 53.23M |
| EPS Basic | -2.52 | -3.22 | -4.59 | -14.18 | 1.79 |
| Normalized Basic EPS | -1.58 | -2.01 | -8.86 | -14.24 | 22.85 |
| EPS Diluted | -2.53 | -3.22 | -4.89 | -14.48 | -6.95 |
| Normalized Diluted EPS | -1.58 | -2.01 | -8.86 | -14.24 | 2.16 |
| Average Basic Shares Outstanding | 196.87M | 171.60M | 120.64M | 77.27M | 35.88M |
| Average Diluted Shares Outstanding | 196.87M | 171.60M | 120.64M | 77.27M | 39.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |